M-CERSI Workshop: Predictive Immunogenicity for Better Clinical Outcomes
Wednesday, October 3, 2018
10:00 a.m.-11:00 a.m.
FDA - White Oak, 10903 New Hampshire Avenue, Silver Spring, MD
Wednesday, October 3, 2018: 8:30 a.m. - 5:00 p.m.
Thursday, October 4, 2018: 8:30 a.m. - 5:00 p.m.
(Sign-in/registration begins at 7:30 a.m. both days)
FDA's White Oak Campus
10903 New Hampshire Avenue
Building #31 - The Great Room
Silver Spring, MD 20903
* Remote viewing available
This public workshop will also be available to view via webcast at no cost, but registration is still required. If you plan to attend or participate in both days of the workshop, please register using both of the below links:
The workshop will be recorded for later viewing.
Goals and Objectives:
Protein therapeutics have continued to gain an increasing share of the pharmaceutical market and now provide medical interventions for some of the most complex and intractable diseases. Immunogenicity, the propensity of a therapeutic protein to induce immune responses, principally by development of antibodies, may affect safety and/or efficacy, and is thus an important concern in the development and regulation of protein therapeutics. Patients, regulators and the biopharmaceutical industry are all affected by immunogenicity. Recently, both the US Food and Drug Administration and the European Medicines Agency have released Guidance Documents for industry focusing on immunogenicity.
This timely public workshop will present advances in the development of technological tools for predictions of immunogenicity and discussions on how to engage relevant stakeholders in application of these tools during drug development.
The specific objectives of this workshop are to:
Communicate to stakeholders the “state of the science” regarding technological approaches for prediction of immunogenicity including non-clinical (in silico) studies for detection of neo-antigens, the use of novel animal models, and strategies to de-immunize protein molecules.
Explore strategies for choosing appropriate tools and interpreting the results since the novel tools and information available in this field are complex and not amenable to simple prescriptive approaches during drug development.
Who Should Attend:
This workshop is open to the public. The intended audience includes those with an interest in immunogenicity of therapeutic proteins and related assessments including the biopharmaceutical industry and related companies, regulators, patient advocacy groups, academic researchers, clinicians involved in patient care and clinical research, government agencies, payors such as insurance companies, medical product policy makers, and the public.
Agenda, Accommodations, Directions, and Parking Information:
Information regarding FDA lodging, ground transportation, airport information, directions, security, parking, and FAQs is available online.
Registration for FDA and non-FDA Attendees:
Remote Access Information/Instructions/Webcast Registration (pre-registration is required):
This public workshop will be available to view via webcast but pre-registration is still required. After you register using the above links, you will receive links via email as Outlook calendar invitations with information on how to access the live webinars. You must log in with your username and password which you create when you register. You must pre-register at least one day before the event to ensure that the access link emails and outlook invitations are received for each day.
For questions and reasonable accommodations:
For questions, please contact FDA-CERSI-Collaborative-Workshop@fda.hhs.gov.